Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMYNYSE / NASDAQHealthcareLarge cap

$58.80+$0.46 (+0.8%)

Last close · Data as of Nov 20, 2026

Market cap
$115.6B
P/E
16.4x
EV / EBITDA
10.0x
Revenue
$48.2B
Net margin
14.6%
ROCE
20.6%

+28.0% over the last year

Bristol-Myers Squibb Company price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-4.7%
3M
-10.2%
6M
+0.4%
1Y
+28.0%
5Y
+1.7%

52-week range

Day change +$0.46 (+0.8%) from $58 to $59 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BMY, bought on each weekday since 2021.

News & filings

What Bristol-Myers Squibb Company filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 28.5% against a peer median of 19.3%.

Concerns (1)

  • Revenue grew 1.4% a year over three years.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.

Read moreShow less

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Sector
Healthcare
Shares outstanding
2.03B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$115.6B
P/E
16.4x
P/B
6.3x
EV / EBITDA
10.0x
EV / Sales
3.2x
P/S
2.4x
52-week high
$68.09
52-week low
$45.94

Profitability

Operating margin
28.5%
Net margin
14.6%
EBITDA margin
31.6%
ROE
38.2%
ROCE
20.6%
ROA
7.8%
Asset turnover
0.54

Growth

Revenue
$48.2B
Revenue growth, 1Y
-0.2%
Revenue CAGR, 3Y
1.4%
Net profit growth, 1Y
-178.8%
Free cash flow
$12.8B

Solvency

Current ratio
1.26
Debt / Equity
2.55
Debt / Assets
0.52
CFO / Net profit
2.01
Cash / Market cap
8.8%

Where the revenue went

Of every $100 of FY2025 revenue, $15 was left as net income.

Bristol-Myers Squibb Company income statement flow, FY2025
Bristol-Myers Squibb Company income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$13.9B
RevenueGross profit$34.3B
Gross profitResearch and development$10.0B
Gross profitSelling, general and administrative$7.3B
Gross profitOther operating expenses$3.3B
Gross profitOperating income$13.7B
Operating incomePretax income$9.3B
Operating incomeInterest and other expense$4.4B
Pretax incomeTax and other$2.3B
Pretax incomeNet income$7.1B

Revenue and net profit

Revenue fell 0.2% in FY2025; net profit is the dashed line.

Bristol-Myers Squibb Company revenue and net profit by fiscal year
Bristol-Myers Squibb Company revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$46.2B$6.3B
FY2023$45.0B$8.0B
FY2024$48.3B-$8.9B
FY2025$48.2B$7.1B

Cash flows

FY2025: $14.2B from operations, $12.8B free after investment (dashed).

Bristol-Myers Squibb Company operating and free cash flow by fiscal year
Bristol-Myers Squibb Company operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$13.1B$11.9B
FY2023$13.9B$12.7B
FY2024$15.2B$13.9B
FY2025$14.2B$12.8B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$48.2B-0.2%1Y
EBITDA
$15.2B+380.7%1Y
Net profit
$7.1B
Cash from operations
$14.2B-6.8%1Y
Free cash flow
$12.8B-7.9%1Y
Revenue CAGR, 3Y
1.4%
Net profit CAGR, 3Y
3.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$48.2B$15.2B$7.1B$12.8B38.2%-0.2%-178.8%

Monthly returns

Month-by-month returns of BMY across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$90.0B
Liabilities$71.5B
Equity$18.5B
Paid-in capital$46.4B
Retained earnings$16.9B
Treasury stock$43.6B
Minority interest$33.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BMY highlighted.

P/E against peers

BMY trades at 16.4x earnings against a peer median of 25.5x (a 36% discount).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Bristol-Myers Squibb CompanyBMYthis companyP/E ↓ discount$115.6B16.4x6.3x38.2%10.0x
Pfizer Inc.PFE$146.4B18.8x1.7x9.0%12.5x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Stryker CorporationSYK$115.5B35.6x5.2x14.5%20.2x
Vertex Pharmaceuticals IncorporatedVRTX$112.1B28.4x6.0x21.2%22.4x
Medtronic plcMDT$105.2B22.6x2.2x9.7%14.3x
McKesson CorporationMCK$91.0B19.1x-41.9x-219.2%13.3x
Elevance Health, Inc.ELV$88.9B15.7x2.0x12.9%—
Peer median—25.5x2.1x9.3%19.5x

Year-to-date ROI

BMY since 1 January, against earlier years.

Historical volatility

BMY's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Bristol-Myers Squibb Company operating margin by fiscal year
Bristol-Myers Squibb Company operating margin by fiscal year
DateOperating margin
FY202219.7%
FY202318.2%
FY202412.2%
FY202528.5%
LineFY2025
Cost of revenueCost Of Revenue$13.9B
Gross profitGross Profit$34.3B
Operating expensesOperating Expense$20.5B
Research and developmentResearch And Development$10.0B
Depreciation and amortisationDepreciation And Amortization In Income Statement$3.3B
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$3.3B
Amortization$3.3B
Amortisation of intangiblesAmortization Of Intangibles Income Statement$3.3B
Total expensesTotal Expenses$34.5B
Operating incomeOperating Income$13.7B
Pretax incomePretax Income$9.3B

Learn while you research

Academy chapters picked for Bristol-Myers Squibb Company and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 2.55 is elevated, understand what that means for solvency.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →